If you order your essay from our custom writing service you will receive a perfectly written assignment on Aspirin and Ticlopidine for Prevention of Recurrent Stroke in Black Patients. What we need from you is to provide us with your detailed paper instructions for our experienced writers to follow all of your specific writing requirements. Specify your order details, state the exact number of pages required and our custom writing professionals will deliver the best quality Aspirin and Ticlopidine for Prevention of Recurrent Stroke in Black Patients paper right on time.
Our staff of freelance writers includes over 120 experts proficient in Aspirin and Ticlopidine for Prevention of Recurrent Stroke in Black Patients, therefore you can rest assured that your assignment will be handled by only top rated specialists. Order your Aspirin and Ticlopidine for Prevention of Recurrent Stroke in Black Patients paper at affordable prices!
Blacks are disproportionately affected by stroke, yet they have been underrepresented in clinical trials. Recommendations for stroke prevention in this population have been based largely on trials that have included few black participants. This may not be an optimal practice because blacks are among those with a higher prevalence of major cardiovascular risk factors, a different distribution of atherosclerotic occlusive cerebral vascular lesions, vascular biological differences such as low renin hypertension, and a different pattern of use of medical procedures and access to care that could influence outcome.
A subgroup analysis of the Ticlopidine Aspirin Stroke Study (TASS)suggested a more favorable risk-benefit profile for nonwhites than whites. Specifically, among the 45 black and 108 nonwhite and nonblack study participants, there was a 4.1% relative risk reduction (RRR) for stroke and death at years favoring ticlopidine (500 mg/d) over aspirin (100 mg/d), and 10% fewer serious adverse events (SAEs). Overall in TASS, there was a 1% RRR for nonfatal stroke or death from any cause (P = .05) favoring ticlopidine at years.
The current study was designed in 1, with the belief that a targeted recurrent stroke prevention study for blacks was justified given their disproportionate stroke burden, promising data for ticlopidine as a recurrent stroke preventive treatment in nonwhites, and the lack of previous substantial representation of blacks in stroke clinical trials. The primary outcome of the African American Antiplatelet Stroke Prevention Study (AAASPS) was the composite end point of recurrent stroke, myocardial infarction, or vascular death.
A description of the design and methods of AAASPS has been reported previously in accordance with criteria proposed by the Consolidated Standards of Reporting Trials. That article16 included a discussion of barriers to black participation in clinical trials and how they were overcome, the rationale for study drug selection, relationships established with primary care physicians, management of cardiovascular risk factors, and other major aspects of the study. The diagnosis of stroke and stroke subtype was determined after review of source documents and case report forms and by application of criteria from the Trial of ORG 1017 in Acute Stroke Treatment (TOAST)1 by local principal investigators for the entry stroke and by the AAASPS adjudication committee for all outcome events. Entry and outcome stroke cases received computed tomography or magnetic resonance imaging of the head.
At the time our study design was developed in the early to mid-10s, we believed that there was uncertainty about the preferred aspirin dose for recurrent stroke prevention. Given this uncertainty, we opted for an aspirin dose of 650 mg/d in accordance with the recommendations by Barnett et al.
Eligibility criteria included black (African American) race; -85 years of age inclusive; noncardioembolic ischemic stroke with onset at least 7 days but not more than 0 days; cranial computed tomographic scan or magnetic resonance image of the brain consistent with occurrence of the entry cerebral infarct; measurable neurological deficit that correlates at onset with entry cerebral infarct; informed consent; and availablity of patient to be followed up in an outpatient treatment program.
Exclusion criteria included transient ischemic attack, subarachnoid hemorrhage, cardiac source embolism, iatrogenic stroke, nonatherosclerotic stroke, postoperative stroke occurring within 0 days of operation, or carotid endarterectomy as primary treatment measure for entry cerebral infarct; mean arterial blood pressure higher than 10 mm Hg on consecutive days; modified Barthel index of less than 10; history of dementia or neurodegenerative disease; severe comorbid condition (eg, cancer) judged to limit survival during -year follow-up; enrollment in another clinical trial; allergy or sensitivity to study drugs; woman of childbearing potential; gastrointestinal tract bleeding, bleeding diathesis, or platelet or other hematologic abnormality (judged to be a contraindication for administration of study drugs) currently active or clinically active in the past year; hematuria or positive stool guaiac test related to major bleeding source; and prolonged prothrombin time or partial thromboplastin time, blood urea nitrogen level higher than 40 mg/dL, serum creatinine level higher than .0 mg/dL (176.8 µmol/L), thrombocytopenia or neutropenia defined by the lower limit of normal for the platelet count or white blood cell count (unless absolute neutrophil count of at least 1800/mm), or liver function tests or more times the upper limit of normal. All sites had to receive formal approval from their institutional review board before the study could commence at a local site.
Please note that this sample paper on Aspirin and Ticlopidine for Prevention of Recurrent Stroke in Black Patients is for your review only. In order to eliminate any of the plagiarism issues, it is highly recommended that you do not use it for you own writing purposes. In case you experience difficulties with writing a well structured and accurately composed paper on Aspirin and Ticlopidine for Prevention of Recurrent Stroke in Black Patients, we are here to assist you. Your essay on Aspirin and Ticlopidine for Prevention of Recurrent Stroke in Black Patients will be written from scratch, so you do not have to worry about its originality. Order your authentic assignment and you will be amazed at how easy it is to complete a quality custom paper within the shortest time possible!